This Medical Stock Soared Over 80% In Pre-Market After Advancing Gene Therapy Program For ALS, Alzheimer's And Parkinson's Diseases
This Medical Stock Soared Over 80% In Pre-Market After Advancing Gene Therapy Program For ALS, Alzheimer's And Parkinson's Diseases
ANEW's development plans encompass FDA Clinical Trials, Klotho Diagnostics, and Age-Related Disorders. In Tuesday's pre-market trading, ANEW Medical, Inc. (NASDAQ:WENA) saw its shares surge nearly 80% following an announcement about the advancement of its patented Klotho gene therapy program for neurodegenerative disorders.
在周二的美股盘前交易中，ANEW Medical，Inc.（纳斯达克：WENA）的股价因其针对神经退行性疾病的专利Klotho基因治疗计划前景的公告而大涨近80％。
What Happened: ANEW, a biopharmaceutical company that specializes in developing innovative therapies for neurological and age-related disorders, was trading at $2.460 at the time of writing, up from Monday's close at $1.450, according to Benzinga Pro data.
发生了什么：ANEW是一家专门从事神经和老年性疾病创新疗法开发的生物制药公司，根据Benzinga Pro的数据，在撰写本文时，该公司的股票价格为2.460美元，与周一的收盘价1.450美元相比有所上涨。
ANEW's preliminary data indicates that maintaining high Klotho levels in the body could result in longer, healthier lives. Conversely, individuals with lower Klotho levels are more susceptible to neurodegenerative disorders such as ALS, Alzheimer's, and Parkinson's Disease. ANEW also intends to explore other age-related disorders associated with reduced Klotho levels.
ANEW的初步数据表明，保持身体中高Klotho水平可能会导致更长寿的健康生活。相反，Klotho水平较低的个体更容易患上肌萎缩侧索硬化症（ALS）、阿尔茨海默病和帕金森病等神经退行性疾病。ANEW还打算探索与降低Klotho水平相关的其他老年性疾病。
ANEW's development plans encompass FDA Clinical Trials, Klotho Diagnostics, and Age-Related Disorders. Dr. Shalom Hirshman, M.D., Chief Medical Advisor and Board member, expressed that ANEW is well-positioned to significantly impact the treatment of ALS, Alzheimer's, and other neurodegenerative disorders.
ANEW的开发计划包括FDA临床试验、Klotho诊断和老年性疾病。首席医学顾问和董事会成员Dr. Shalom Hirshman认为，ANEW有望在显著影响ALS、阿尔茨海默病和其他神经退行性疾病的治疗方面具有良好的地位。
Why It Matters: ANEW's advancements come amid a broader industry focus on neurodegenerative disorders. A recent study highlighted the complexities of Alzheimer's disease.
为什么重要：ANEW的进展是在整个医疗行业关注神经退行性疾病的背景下出现的。最近的一项研究强调了阿尔茨海默病的复杂性。
In June, Eli Lilly received FDA approval for its Alzheimer's therapy, Kisunla. Furthermore, they expanded their neuro pipeline with the addition of a preclinical ALS, dementia prospect. Even tech companies like Synchron Inc., backed by Jeff Bezos and Bill Gates, are entering the fray with plans to treat Parkinson's and epilepsy.
今年6月，Eli Lilly收到了针对阿尔茨海默病的Kisunla疗法的FDA批准。此外，他们还通过加入一个临床前ALS、痴呆前途的其它神经产品，扩大了他们的神经治疗项目。甚至像由Jeff Bezos和Bill Gates支持的Synchron公司这样的科技公司也计划治疗帕金森病和癫痫。
- Why Is HilleVax Stock Trading Lower On Monday?
- 为什么HilleVax股票周一交易下跌？
Photo: Courtesy of Marcin Janiec via Shutterstock
照片：由Shutterstock的Marcin Janiec免费提供
This story was generated using Benzinga Neuro and edited by Pooja Rajkumari
本报道使用Benzinga Neuro生成，并由Pooja Rajkumari编辑
